0A8E.LSE Xeris Biopharma Holdings, Inc.

Healthcare Drug Manufacturers - Specialty & Generic London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0A8E.LSE undervalued?

Graham number

The Graham number of Xeris Biopharma Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Xeris Biopharma Holdings, Inc. fundamental analysis

No fundamental analysis for Xeris Biopharma Holdings, Inc. yet.

Xeris Biopharma Holdings, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhib…

Full company profile